# Tazemetostat Plus CHOP in 1L T-cell Lymphoma

> **NCT06692452** · PHASE2 · WITHDRAWN · sponsor: **Eric Jacobsen, MD**

## Conditions studied

- Lymphoma
- Peripheral T Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

## Interventions

- **DRUG:** Tazemetostat
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Cytoxan
- **DRUG:** Carmustine
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT06692452
- **Lead sponsor:** Eric Jacobsen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-24
- **Primary completion:** 2027-10-01
- **Final completion:** 2032-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Ipsen requested a temporary closure due to a safety concern.
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06692452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06692452, "Tazemetostat Plus CHOP in 1L T-cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06692452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*